AR064715A1 - Composiciones farmaceuticas inyecatbles liofilizadas de derivados semi- sinteticos de los alcaloides de vinca estables a temperatura ambiente - Google Patents

Composiciones farmaceuticas inyecatbles liofilizadas de derivados semi- sinteticos de los alcaloides de vinca estables a temperatura ambiente

Info

Publication number
AR064715A1
AR064715A1 ARP070105992A ARP070105992A AR064715A1 AR 064715 A1 AR064715 A1 AR 064715A1 AR P070105992 A ARP070105992 A AR P070105992A AR P070105992 A ARP070105992 A AR P070105992A AR 064715 A1 AR064715 A1 AR 064715A1
Authority
AR
Argentina
Prior art keywords
semi
stable
pharmaceutical compositions
liofilized
synthetic derivatives
Prior art date
Application number
ARP070105992A
Other languages
English (en)
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38293420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064715(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of AR064715A1 publication Critical patent/AR064715A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Composiciones farmacéuticas que comprenden un derivado hidrosoluble semi-sintético del alcaloide de la vinca, estables a la temperatura ambiente, en los cuales dicho derivado está presente bajo la forma de un liofilizado obtenido en presencia de por lo menos un carbohidrato. Reivindicacion 3: Composiciones de acuerdo a la reivindicacion 2, caracterizadas en que la sal hidrosoluble de los derivados semi-sintéticos del alcaloide de la vinca es una sal de vinfluvina o de vinorelbina. Reivindicacion 5: Composiciones de acuerdo de una de las reivindicaciones 1 a 4, caracterizadas en que el/los carbohidrato(s) es(son) elegido(s) entre los monosacáridos, reducidos o no, los oligosacáridos y los polisacáridos tales como la inulina, y más particularmente los disacáridos.
ARP070105992A 2006-12-29 2007-12-28 Composiciones farmaceuticas inyecatbles liofilizadas de derivados semi- sinteticos de los alcaloides de vinca estables a temperatura ambiente AR064715A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0656044A FR2910812B1 (fr) 2006-12-29 2006-12-29 Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante
US89705907P 2007-01-24 2007-01-24

Publications (1)

Publication Number Publication Date
AR064715A1 true AR064715A1 (es) 2009-04-22

Family

ID=38293420

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105992A AR064715A1 (es) 2006-12-29 2007-12-28 Composiciones farmaceuticas inyecatbles liofilizadas de derivados semi- sinteticos de los alcaloides de vinca estables a temperatura ambiente

Country Status (24)

Country Link
US (1) US8304424B2 (es)
EP (1) EP2120934B1 (es)
JP (1) JP2010514737A (es)
KR (1) KR20090097883A (es)
CN (1) CN101534821B (es)
AR (1) AR064715A1 (es)
AU (1) AU2007341231B2 (es)
BR (1) BRPI0722076A2 (es)
CA (1) CA2673232A1 (es)
CL (1) CL2007003838A1 (es)
FR (1) FR2910812B1 (es)
HK (1) HK1130439A1 (es)
IL (1) IL199556A (es)
MA (1) MA30892B1 (es)
MX (1) MX2009006949A (es)
NO (1) NO20092726L (es)
NZ (1) NZ576583A (es)
RU (1) RU2449791C2 (es)
SA (1) SA07280720B1 (es)
TN (1) TN2009000258A1 (es)
TW (1) TWI415631B (es)
UA (1) UA96977C2 (es)
WO (1) WO2008080968A1 (es)
ZA (1) ZA200903115B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102151249A (zh) * 2010-02-11 2011-08-17 石药集团中奇制药技术（石家庄）有限公司 一种长春氟宁的药用组合物
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
CN102772373B (zh) * 2011-05-11 2015-09-02 石药集团中奇制药技术（石家庄）有限公司 一种注射用酒石酸长春瑞滨粉针剂及其制备方法
AU2019331886B2 (en) * 2018-08-31 2023-10-19 FUJIFILM Irvine Scientific, Inc. Venting system for a mixing apparatus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1170152B (it) * 1982-07-19 1987-06-03 Lilly Co Eli Miglioramenti a o riguardanti formulazioni di vinca-alcaloidi
US4619935A (en) * 1983-03-17 1986-10-28 Eli Lilly And Company Stable oncolytic formulations
US4923876A (en) * 1988-04-18 1990-05-08 Cetus Corporation Vinca alkaloid pharmaceutical compositions
HUT54308A (en) * 1989-04-04 1991-02-28 Lilly Co Eli Process for producing immunoglobulin conjugates and medicaments comprising same
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
FR2761990B1 (fr) * 1997-04-10 1999-06-25 Pf Medicament Derives halogenes antimitotiques d'alcaloides de vinca
PL205936B1 (pl) * 2002-02-22 2010-06-30 Schering Corp Farmaceutyczny preparat zawierający termozolomid oraz sposób jego wytwarzania
FR2863891B1 (fr) 2003-12-23 2006-03-24 Pf Medicament Composition pharmaceutique de vinflunine destinee a une administration parentale, procede de preparation et utilisation
KR101462825B1 (ko) * 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
CA2602089C (en) * 2005-03-14 2013-04-30 Wyeth Tigecycline compositions and methods of preparation

Also Published As

Publication number Publication date
US8304424B2 (en) 2012-11-06
ZA200903115B (en) 2010-04-28
UA96977C2 (ru) 2011-12-26
KR20090097883A (ko) 2009-09-16
CL2007003838A1 (es) 2008-07-04
TWI415631B (zh) 2013-11-21
AU2007341231A1 (en) 2008-07-10
TW200833369A (en) 2008-08-16
RU2449791C2 (ru) 2012-05-10
TN2009000258A1 (en) 2010-10-18
IL199556A (en) 2014-09-30
FR2910812B1 (fr) 2009-03-20
WO2008080968A1 (en) 2008-07-10
JP2010514737A (ja) 2010-05-06
HK1130439A1 (en) 2009-12-31
RU2009128327A (ru) 2011-02-10
EP2120934B1 (en) 2014-05-07
EP2120934A1 (en) 2009-11-25
CN101534821B (zh) 2012-01-25
AU2007341231B2 (en) 2013-03-21
NO20092726L (no) 2009-07-20
MA30892B1 (fr) 2009-11-02
US20100087473A1 (en) 2010-04-08
BRPI0722076A2 (pt) 2014-04-08
SA07280720B1 (ar) 2012-02-07
NZ576583A (en) 2012-01-12
MX2009006949A (es) 2009-07-14
FR2910812A1 (fr) 2008-07-04
CN101534821A (zh) 2009-09-16
CA2673232A1 (en) 2008-07-10

Similar Documents

Publication Publication Date Title
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
CR20150097A (es) Composición inmunogénica
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
AR089291A1 (es) Edulcorante natural y metodo de elaboracion
AR072212A1 (es) Una composicion farmaceutica que comprende rebamipida
BR112015013124A2 (pt) novos derivados de piridina
BR112012013847A2 (pt) novos derivados de indolinona ciclopropano
BR112012026338A2 (pt) novos derivados de 3,3-dimetil tetrahidroquinolina
BR112015022782A2 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
BRPI0916286B8 (pt) amidofenóxi-indazóis úteis como inibidores de c-met, seus usos, e composição farmacêutica
NI200800318A (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina.
AR064715A1 (es) Composiciones farmaceuticas inyecatbles liofilizadas de derivados semi- sinteticos de los alcaloides de vinca estables a temperatura ambiente
GT200600084A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
BR112015029853A2 (pt) uso de uma composição farmacêutica
MX2015006124A (es) Inhibidores del contransportador 1 de sodio glucosa.
CO6270306A2 (es) Compuesto inhibidor de glicogeno fosforilasa y composicion farmaceutica del mismo
CO6400185A2 (es) Formas de dosificación sólida de bendamustina
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
BRPI0818541B8 (pt) composição farmacêutica que compreende grânulos incluindo picossulfato de sódio e bicarbonato de potássio e seu processo para a preparação
BR112014020416A2 (pt) Sal de 1-(2-desoxi-2-flúor-4-tio-b-d-arabinofuranosil) citosina
AR056835A1 (es) Composicion que contiene oligosacaridos
BR112015013783A2 (pt) quitina ou seus derivados para a prevenção e / ou tratamento de parasitoses
BR112015027396A2 (pt) derivados de purina como agonistas do receptor de cb2
BR112014014700A2 (pt) fibras de polilactídeo
UY31138A1 (es) Derivados de indolinonas sustituidas, composiciones conteniendolos y aplicaciones

Legal Events

Date Code Title Description
FB Suspension of granting procedure